Melanoma vaccines in development

Ruggero Ridolfi, Laura Ridolfi, Stefania V L Nicoletti, Massimo Guidoboni

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The immune system has the capacity to discriminate between self and nonself forms. However, within the tumor microenvironment, there are numerous mechanisms of immunosuppression that contrast this process in vivo. An antitumor vaccine is a therapeutic strategy that promotes a strong immune-specific response aimed at recognizing and killing tumor cells. It must be capable of maintaining such properties over time and of overcoming tumor immunosuppression. There are several methods for creating a vaccine therapy, all currently undergoing investigation, for example, patients can be injected with one or more peptides of known antigens or else protein components derived from tumor cells (autologous or allogenic). Another method involves the in vitro culture of immunocompetent cells such as dendritic cells, which are then reinjected into the patient. Despite the failure of both adjuvant and advanced therapy in most clinical trials, some encouraging results induced researchers to continue, especially because a strong vaccine-induced immunostimulation seems to correlate positively with clinical outcome, in particular, survival. In the not-too-distant future, gene-expression profiling could help in selecting patients who are likely to benefit from such treatments and could also facilitate the identification of new therapeutic approaches to overcome tumor immunosuppression.

Original languageEnglish
Title of host publicationEmerging Therapeutics for Melanoma
PublisherFuture Medicine Ltd.
Pages105-119
Number of pages15
ISBN (Print)9781780840321, 9781780841168
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Melanoma
Vaccines
Immunosuppression
Neoplasms
Active Immunotherapy
Tumor Microenvironment
Gene Expression Profiling
Therapeutics
Dendritic Cells
Immune System
Immunization
Cell Culture Techniques
Research Personnel
Clinical Trials
Antigens
Peptides
Survival
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ridolfi, R., Ridolfi, L., Nicoletti, S. V. L., & Guidoboni, M. (2012). Melanoma vaccines in development. In Emerging Therapeutics for Melanoma (pp. 105-119). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.181

Melanoma vaccines in development. / Ridolfi, Ruggero; Ridolfi, Laura; Nicoletti, Stefania V L; Guidoboni, Massimo.

Emerging Therapeutics for Melanoma. Future Medicine Ltd., 2012. p. 105-119.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ridolfi, R, Ridolfi, L, Nicoletti, SVL & Guidoboni, M 2012, Melanoma vaccines in development. in Emerging Therapeutics for Melanoma. Future Medicine Ltd., pp. 105-119. https://doi.org/10.2217/EBO.11.181
Ridolfi R, Ridolfi L, Nicoletti SVL, Guidoboni M. Melanoma vaccines in development. In Emerging Therapeutics for Melanoma. Future Medicine Ltd. 2012. p. 105-119 https://doi.org/10.2217/EBO.11.181
Ridolfi, Ruggero ; Ridolfi, Laura ; Nicoletti, Stefania V L ; Guidoboni, Massimo. / Melanoma vaccines in development. Emerging Therapeutics for Melanoma. Future Medicine Ltd., 2012. pp. 105-119
@inbook{5dd462f73af342908c79dfb7657fec54,
title = "Melanoma vaccines in development",
abstract = "The immune system has the capacity to discriminate between self and nonself forms. However, within the tumor microenvironment, there are numerous mechanisms of immunosuppression that contrast this process in vivo. An antitumor vaccine is a therapeutic strategy that promotes a strong immune-specific response aimed at recognizing and killing tumor cells. It must be capable of maintaining such properties over time and of overcoming tumor immunosuppression. There are several methods for creating a vaccine therapy, all currently undergoing investigation, for example, patients can be injected with one or more peptides of known antigens or else protein components derived from tumor cells (autologous or allogenic). Another method involves the in vitro culture of immunocompetent cells such as dendritic cells, which are then reinjected into the patient. Despite the failure of both adjuvant and advanced therapy in most clinical trials, some encouraging results induced researchers to continue, especially because a strong vaccine-induced immunostimulation seems to correlate positively with clinical outcome, in particular, survival. In the not-too-distant future, gene-expression profiling could help in selecting patients who are likely to benefit from such treatments and could also facilitate the identification of new therapeutic approaches to overcome tumor immunosuppression.",
author = "Ruggero Ridolfi and Laura Ridolfi and Nicoletti, {Stefania V L} and Massimo Guidoboni",
year = "2012",
month = "1",
day = "1",
doi = "10.2217/EBO.11.181",
language = "English",
isbn = "9781780840321",
pages = "105--119",
booktitle = "Emerging Therapeutics for Melanoma",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Melanoma vaccines in development

AU - Ridolfi, Ruggero

AU - Ridolfi, Laura

AU - Nicoletti, Stefania V L

AU - Guidoboni, Massimo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The immune system has the capacity to discriminate between self and nonself forms. However, within the tumor microenvironment, there are numerous mechanisms of immunosuppression that contrast this process in vivo. An antitumor vaccine is a therapeutic strategy that promotes a strong immune-specific response aimed at recognizing and killing tumor cells. It must be capable of maintaining such properties over time and of overcoming tumor immunosuppression. There are several methods for creating a vaccine therapy, all currently undergoing investigation, for example, patients can be injected with one or more peptides of known antigens or else protein components derived from tumor cells (autologous or allogenic). Another method involves the in vitro culture of immunocompetent cells such as dendritic cells, which are then reinjected into the patient. Despite the failure of both adjuvant and advanced therapy in most clinical trials, some encouraging results induced researchers to continue, especially because a strong vaccine-induced immunostimulation seems to correlate positively with clinical outcome, in particular, survival. In the not-too-distant future, gene-expression profiling could help in selecting patients who are likely to benefit from such treatments and could also facilitate the identification of new therapeutic approaches to overcome tumor immunosuppression.

AB - The immune system has the capacity to discriminate between self and nonself forms. However, within the tumor microenvironment, there are numerous mechanisms of immunosuppression that contrast this process in vivo. An antitumor vaccine is a therapeutic strategy that promotes a strong immune-specific response aimed at recognizing and killing tumor cells. It must be capable of maintaining such properties over time and of overcoming tumor immunosuppression. There are several methods for creating a vaccine therapy, all currently undergoing investigation, for example, patients can be injected with one or more peptides of known antigens or else protein components derived from tumor cells (autologous or allogenic). Another method involves the in vitro culture of immunocompetent cells such as dendritic cells, which are then reinjected into the patient. Despite the failure of both adjuvant and advanced therapy in most clinical trials, some encouraging results induced researchers to continue, especially because a strong vaccine-induced immunostimulation seems to correlate positively with clinical outcome, in particular, survival. In the not-too-distant future, gene-expression profiling could help in selecting patients who are likely to benefit from such treatments and could also facilitate the identification of new therapeutic approaches to overcome tumor immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=84956725647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956725647&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.181

DO - 10.2217/EBO.11.181

M3 - Chapter

AN - SCOPUS:84956725647

SN - 9781780840321

SN - 9781780841168

SP - 105

EP - 119

BT - Emerging Therapeutics for Melanoma

PB - Future Medicine Ltd.

ER -